Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.

被引：1
|
作者：
Lopez, Juanita Suzanne
Plummer, Elizabeth Ruth
Devlin, Michael-John
Rulach, Robert
Garces, Alvaro Henrique Ingles
Haris, Noor R. Md
Miller, Rowan
Crawford, Donna
D'Arcangelo, Manolo
Aversa, Caterina
Hannah, Alison L.
Anderson, Stephanie
Engelhardt, Marc Frederick
Kaindl, Thomas
Larger, Patrice
Bachmann, Felix
Lane, Heidi A.
McKernan, Phil
Evans, T. R. Jeffry
Kristeleit, Rebecca Sophie
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Coll London Hosp, London, England
[5] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[6] UCL, Canc Inst, London, England
[7] Oncol Clin Trial Consulting, Sebastopol, CA USA
[8] Basilea Pharmaceut Int Ltd, Basel, Switzerland
[9] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2530
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.
    Lopez, Juanita
    Evans, T. R. Jeffry
    Plummer, Elizabeth R.
    Diamantis, Nikolaos
    Shaw, Heather May
    Zubairi, Ishtiaq Husain
    Haris, Noor R. Md
    MacDonald, Julie
    Greystoke, Alastair
    Roux, Rene Lynnette
    Tunariu, Nina
    Molife, L. Rhoda
    Hannah, Alison L.
    Anderson, Stephanie
    Lane, Heidi A.
    Maurer, Martina
    Schmitt-Hoffmann, Anne
    Bachmann, Felix
    Engelhardt, Marc Frederick
    Kristeleit, Rebecca Sophie
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.
    Joerger, Markus
    Metaxas, Ioannis
    Stathis, Anastasios
    Hess, Dagmar
    Mark, Michael Thomas
    Hutter, Franziska
    Levy, Nicole
    Stuedeli, Silvia
    Berardi, Simona
    Landau-Salzberg, Michele
    Engelhardt, Marc Frederick
    Larger, Patrice
    Kaindl, Thomas
    Hafner, Peter
    McKernan, Phil
    Lane, Heidi A.
    Von Moos, Roger Anton Fredy
    Sessa, Cristiana
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] A Phase 1 study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Evans, T. R. Jeffry
    Lopez, Juanita
    Slater, Sarah
    D'Arcangelo, Manolo
    Drew, Yvette
    Adeleke, Sola
    Brown, Jessica
    Crawford, Donna
    Diamantis, Nikolaos
    Gougis, Paul
    Tzankov, Alexandar
    Hannah, Alison L.
    Anderson, Stephanie
    Lane, Heidi A.
    Schmitt-Hoffmann, Anne
    Maurer, Martina
    Bachmann, Felix
    Engelhardt, Marc Frederick
    Plummer, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.
    Lopez, Juanita Suzanne
    Kristeleit, Rebecca Sophie
    Rulach, Robert
    Haris, Noor Md
    Scaranti, Mariana
    Mulholland, Paul James
    Crawford, Donna
    Bashir, Saira
    Aversa, Caterina
    Hannah, Alison L.
    Anderson, Stephanie
    Engelhardt, Marc
    Kaindl, Thomas
    Larger, Patrice
    McKernan, Phil
    Evans, T. R. Jeffry
    Plummer, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Phase 1/2a study of BAL101553, a novel tumor checkpoint controller, administered as 48-h infusion in patients with advanced solid tumors
    Joerger, Markus
    Mark, Michael
    Stathis, Anastasios
    Hess, Dagmar
    Stuedeli, Silvia
    Berardi, Simona
    Kaindl, Thomas
    Larger, Patrice
    Von Moos, Roger
    Sessa, Cristiana
    SWISS MEDICAL WEEKLY, 2018, 148 : 18S - 18S
  • [6] Phase 1/2a trial of daily oral BALI 01553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.
    Kristeleit, Rebecca Sophie -
    Evans, T. R. Jeffry
    Garces, Alvaro Henrique Ingles
    Slater, Sarah
    Drew, Yvette
    Devlin, Michael -John
    Haris, Noor R. Md
    Diamantis, Nikolaos
    MacDonald, Julie
    Bachmann, Felix
    Hannah, Alison L.
    Anderson, Stephanie
    Lane, Heidi A.
    Schmitt-Hoffmann, Anne
    McKernan, Phil
    Engelhardt, Marc Frederick
    Greystoke, Alastair
    Miller, Rowan
    Plummer, Elizabeth R.
    Lopez, Juanita Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
    Kristeleit, Rebecca
    Evans, Jeffry
    Molife, L. Rhoda
    Tunariu, Nina
    Shaw, Heather
    Slater, Sarah
    Haris, Noor R. Md
    Brown, Nicholas F.
    Forster, Martin D.
    Diamantis, Nikolaos
    Rulach, Robert
    Greystoke, Alastair
    Asghar, Uzma
    Rata, Mihaela
    Anderson, Stephanie
    Bachmann, Felix
    Hannah, Alison
    Kaindl, Thomas
    Lane, Heidi A.
    Larger, Patrice J.
    Schmitt-Hoffmann, Anne
    Engelhardt, Marc
    Tzankov, Alexandar
    Plummer, Ruth
    Lopez, Juanita
    BRITISH JOURNAL OF CANCER, 2020, 123 (09) : 1360 - 1369
  • [8] A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
    Markus Joerger
    Anastasios Stathis
    Yannis Metaxas
    Dagmar Hess
    Mara Mantiero
    Michael Mark
    Matthias Volden
    Thomas Kaindl
    Marc Engelhardt
    Patrice Larger
    Heidi Lane
    Peter Hafner
    Nicole Levy
    Silvia Stuedeli
    Cristiana Sessa
    Roger von Moos
    Investigational New Drugs, 2020, 38 : 1067 - 1076
  • [9] Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
    Rebecca Kristeleit
    Jeffry Evans
    L. Rhoda Molife
    Nina Tunariu
    Heather Shaw
    Sarah Slater
    Noor R. Md Haris
    Nicholas F. Brown
    Martin D. Forster
    Nikolaos Diamantis
    Robert Rulach
    Alastair Greystoke
    Uzma Asghar
    Mihaela Rata
    Stephanie Anderson
    Felix Bachmann
    Alison Hannah
    Thomas Kaindl
    Heidi A. Lane
    Patrice J. Larger
    Anne Schmitt-Hoffmann
    Marc Engelhardt
    Alexandar Tzankov
    Ruth Plummer
    Juanita Lopez
    British Journal of Cancer, 2020, 123 : 1360 - 1369
  • [10] A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
    Joerger, Markus
    Stathis, Anastasios
    Metaxas, Yannis
    Hess, Dagmar
    Mantiero, Mara
    Mark, Michael
    Volden, Matthias
    Kaindl, Thomas
    Engelhardt, Marc
    Larger, Patrice
    Lane, Heidi
    Hafner, Peter
    Levy, Nicole
    Stuedeli, Silvia
    Sessa, Cristiana
    von Moos, Roger
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1067 - 1076
12345